Bristol-Myers Squibb's codevelopment and commercialization agreement with AstraZeneca for two diabetes compounds does not include change-in-control provisions, Bristol CFO Andrew Bonfield says during a Jan. 25 earnings call. Bristol has been rumored to be an acquisition candidate since the launch of Plavix generics, although the AstraZeneca partnership, announced Jan. 11, suggests that the firm plans to remain independent (1"The Pink Sheet" Jan. 15, 2007, p. 16)...
You may also be interested in...
Bristol-Myers Squibb's partnership with AstraZeneca for two of its top diabetes candidates may diminish chances that Bristol will be merged
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.